To: 5.1.5 5.1.2e @rivm.nl]

From: 5.1.2e 5.1.2e Sent: Wed 3/17/2021 6:36:47 PM

Subject: RE: EVAg order 6211

Received: Wed 3/17/2021 6:36:47 PM

Hi,

I don't see a problem.

- a. We can agree bilaterally outside the MTA that they can use the material for EQA panels within country. "The RECIPIENT agrees to refer to the EVA-GLOBAL PARTNER any request for the MATERIAL from anyone other than those persons working under the RECIPIENT SCIENTIST's direct supervision."
- b. 24 months: we can change that how we like, so we can agree for them to maintain it in their collection.
- c. Ok, indicate ok and that we would appreciate to be acknowledged in any manuscript using the strain.

So change the date to indefinitely. Add that we can agree bilaterally , outside the MTA, for use for national capacity building. Official request to me by e-mail.

 From:
 5.1.2e
 @rivm.nl>

 Sent:
 woensdag 17 maart 2021 18:50

 To:
 5.1.2e
 5.1.2e
 @rivm.nl>

 Subject:
 FW:
 EVAg order 6211

Hi 5.1.2e

We received these questions for a TNA order. The first email was sent out a while ago and did not incl. the new sentence that the MTA cannot be changed. I was wondering how to best proceed? I have an answer for point 1 and 3, but I don't know what to do with point 2. If it were a commercial order, I would just say no. Do we also proceed like this for a TNA?

Best,



Dear 5.1.2e 5.1.2e ,

We have now reviewed the MTA and we wish to add a few changes.

Please find the new version attached for your evaluation.

In brief:

- 1) We would very much like to incorporate this isolate in our virus collection, and wish therefore <u>not</u> to destruct the material. Would this be possible?
- 2) As a national reference lab, we provide positive controls to SARS-CoV-2 test centers and hospitals at no charge. Could this agreement cover such an activity (<u>inactivated</u> virus material only)?
- 3) Finally, we would like to use the material in our basic research, evaluating the immune response against virus infections as well as vaccines (ours and others').

The material itself would <u>not</u> be used as a vaccine or vaccine component.

Looking forward to hearing from you and please let me know if you have any questions.

And thank you for accepting a signed pdf version in advance to speed up things.

Warmest regards



From: 5.1.2e 5.1.2e

Sent: Friday, February 26, 2021 16:11

To: 5.1.2e Cc: 5.1.2e | 5.1.2e Subject: EVAg order 6211

Dear 5.1.2e

Thank you for your EVAg order with us. Please find attached the MTA for your review. Please add the missing information in the lines that are highlighted in yellow. The free of charge access was granted by EVAg.

Once you reviewed the MTA, I can send you the final file for signature. After you receive the final file, please print and sign 2 copies of the MTA and send them both via regular mail to me:

National Institute for Public Health and the Environment (RIVM)

5.1.2e 5.1.2e

A. van Leeuwenhoeklaan 9, 3721 MA Bilthoven

The Netherlands

In order to speed up the process, we can prepare the shipping in the meantime, if you send me a scanned version of the file.

Once the MTA is completed, we can organize the shipment.

If you have any questions, please let me know.

Best wishes,
5.1.2e 5.1.2e @rivm.nl

Dit bericht kan informatie bevatten die niet voor u is bestemd. Indien u niet de geadresseerde bent of dit bericht abusievelijk aan u is verzonden, wordt u verzocht dat aan de afzender te melden en het bericht te verwijderen. Het RIVM aanvaardt geen aansprakelijkheid voor schade, van welke aard ook, die verband houdt met risico's verbonden aan het elektronisch verzenden van berichten.

www.rivm.nl De zorg voor morgen begint vandaag

This message may contain information that is not intended for you. If you are not the addressee or if this message was sent to you by mistake, you are requested to inform the sender and delete the message. RIVM accepts no liability for damage of any kind resulting from the risks inherent in the electronic transmission of messages.

www.rivm.nl/en Committed to health and sustainability

5 Artillerivej | DK-2300 Copenhagen S | T

5.1.2e

F +45 3268 3868 | E 5.1.2e @ssi.dk | W ssi.dk

This e-mail, inclusive of attachments, is intended for the person(s) or entity stated above and may contain confidential information. Unauthorised reading, disclosure, copying, distribution or use of this information may violate rights to proprietary information. If you are not an intended recipient, please return this e-mail to the sender and delete your copy. Thank you.